Serum Endocan Levels in Postmenopausal Women with Metabolic Syndrome
Metabolic Syndrome and Related Disorders · 2023
DOI: 10.1089/met.2023.0119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Metabolic Syndrome and Related Disorders, 2023. Verfasst von Aleksandra Klisic und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Montenegro-Faculty of Medicine, Podgorica, Montenegro. Hauptthemen laut MEDLINE: Metabolic Syndrome, Diabetes Mellitus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Aim
Studies that explored endocan (as a novel marker of endothelial dysfunction) in relation to metabolic syndrome (MetS) are scarce and show discordant results. Importantly, no study has yet examined serum endocan levels in exclusively postmenopausal women with MetS and free of diabetes. Oxidative stress and inflammation are the key features of MetS and consequently cardiovascular diseases. Hence, we aimed to explore the potential relationship between endocan, oxidative stress [i.e., determined by total antioxidant status, total oxidant status, and pro-oxidant/antioxidant balance (PAB)], inflammation, and MetS in a cohort of postmenopausal women.
Methods
A total of 126 postmenopausal women were included consecutively. MetS was diagnosed following the International Diabetes Federation criteria.
Results
Higher serum endocan levels were found in MetS group as compared with MetS-free counterparts [6.03 (3.47-10.37) pg/mL vs. 2.27 (1.49-3.50) pg/mL, P < 0.001]. Endocan showed good discriminatory ability toward MetS [area under the curve (AUC) = 0.809]. Besides age, the inclusion of oxidative stress and inflammation biomarkers, such as PAB and high-sensitivity C-reactive protein (hsCRP), the AUC for discrimination postmenopausal women with MetS from MetS-free women was 0.845.
Conclusion
Postmenopausal women with MetS exhibited almost 2.7 times higher serum endocan level as compared with MetS-free middle-aged women. Endocan showed good discriminatory ability toward MetS and could be a diagnostic marker in MetS. Similar results were confirmed when added an age, oxidative stress, and inflammation biomarkers (i.e., PAB and hsCRP) were included for the discrimination of postmenopausal with MetS from MetS-free women.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Montenegro-Faculty of Medicine, Podgorica, Montenegro.
- Center for Laboratory Diagnostics, Primary Health Care Center, Podgorica, Montenegro.
- Department for Medical Biochemistry, University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia.
- Outpatient Department of Cardiometabolic Medicine, Second Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration," Thessaloniki, Greece.
ORCID-Profile: Aleksandra Klisic
Zitieren
APA
Klisic, A., Kotur-Stevuljevic, J., Patoulias, D., & Ninic, A. (2023). Serum Endocan Levels in Postmenopausal Women with Metabolic Syndrome. Metabolic Syndrome and Related Disorders. https://doi.org/10.1089/met.2023.0119
Vancouver
Klisic A, Kotur-Stevuljevic J, Patoulias D, Ninic A. Serum Endocan Levels in Postmenopausal Women with Metabolic Syndrome. Metabolic Syndrome and Related Disorders. 2023. doi:10.1089/met.2023.0119
BibTeX
@article{Klisic2023,
author = {Klisic, Aleksandra and Kotur-Stevuljevic, Jelena and Patoulias, Dimitrios and Ninic, Ana},
title = {Serum Endocan Levels in Postmenopausal Women with Metabolic Syndrome},
journal = {Metabolic Syndrome and Related Disorders},
year = {2023},
doi = {10.1089/met.2023.0119}
}
EUVIMED